Free Trial

Affimed (AFMD) Competitors

Affimed logo
$3.26
+0.03 (+0.93%)
(As of 11/1/2024 ET)

AFMD vs. PROC, ZNTL, FULC, DRUG, OGI, ZURA, SCLX, ATAI, DMAC, and ATOS

Should you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Procaps Group (PROC), Zentalis Pharmaceuticals (ZNTL), Fulcrum Therapeutics (FULC), Bright Minds Biosciences (DRUG), Organigram (OGI), Zura Bio (ZURA), Scilex (SCLX), Atai Life Sciences (ATAI), DiaMedica Therapeutics (DMAC), and Atossa Therapeutics (ATOS). These companies are all part of the "pharmaceutical products" industry.

Affimed vs.

Affimed (NASDAQ:AFMD) and Procaps Group (NASDAQ:PROC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.

In the previous week, Affimed had 3 more articles in the media than Procaps Group. MarketBeat recorded 3 mentions for Affimed and 0 mentions for Procaps Group. Affimed's average media sentiment score of 0.57 beat Procaps Group's score of 0.00 indicating that Affimed is being referred to more favorably in the media.

Company Overall Sentiment
Affimed Positive
Procaps Group Neutral

Affimed presently has a consensus target price of $20.00, suggesting a potential upside of 513.50%. Given Affimed's higher probable upside, equities research analysts clearly believe Affimed is more favorable than Procaps Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Affimed
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Procaps Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Procaps Group has higher revenue and earnings than Affimed.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Affimed$2.68M18.49-$114.66MN/AN/A
Procaps Group$409.92MN/A$42.54M$0.523.43

30.8% of Affimed shares are owned by institutional investors. 3.8% of Affimed shares are owned by insiders. Comparatively, 19.9% of Procaps Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Procaps Group has a net margin of 0.00% compared to Affimed's net margin of -2,922.74%. Procaps Group's return on equity of 0.00% beat Affimed's return on equity.

Company Net Margins Return on Equity Return on Assets
Affimed-2,922.74% -155.30% -92.65%
Procaps Group N/A N/A N/A

Affimed has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Procaps Group has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.

Affimed received 432 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 70.16% of users gave Affimed an outperform vote while only 37.50% of users gave Procaps Group an outperform vote.

CompanyUnderperformOutperform
AffimedOutperform Votes
435
70.16%
Underperform Votes
185
29.84%
Procaps GroupOutperform Votes
3
37.50%
Underperform Votes
5
62.50%

Summary

Affimed beats Procaps Group on 8 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AFMD vs. The Competition

MetricAffimedPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$49.64M$7.42B$5.54B$8.53B
Dividend YieldN/A7.96%5.13%4.14%
P/E RatioN/A9.93114.8115.14
Price / Sales18.49396.631,495.55100.10
Price / CashN/A47.3939.6734.08
Price / Book0.785.324.665.02
Net Income-$114.66M$153.56M$119.06M$225.46M
7 Day Performance-1.95%0.13%0.80%0.37%
1 Month Performance-0.91%15.23%5.65%3.57%
1 Year Performance-6.86%41.14%36.75%29.43%

Affimed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AFMD
Affimed
3.7626 of 5 stars
$3.26
+0.9%
$20.00
+513.5%
-8.3%$49.64M$2.68M0.0076News Coverage
PROC
Procaps Group
0.5874 of 5 stars
$1.80
-4.8%
N/A-35.3%$203.08M$414.10M3.465,500Gap Down
ZNTL
Zentalis Pharmaceuticals
1.5732 of 5 stars
$2.84
+0.4%
$10.78
+279.5%
-79.7%$201.95MN/A-1.04160Upcoming Earnings
FULC
Fulcrum Therapeutics
3.4943 of 5 stars
$3.23
-0.3%
$9.33
+189.0%
-14.4%$201.56M$81.63M-9.23100Upcoming Earnings
Short Interest ↓
Positive News
DRUG
Bright Minds Biosciences
1.1803 of 5 stars
$45.10
-5.3%
N/A+3,416.8%$199.97MN/A-66.32N/A
OGI
Organigram
0.6422 of 5 stars
$1.83
-2.7%
N/A+68.0%$198.71M$161.08M-4.36860Positive News
ZURA
Zura Bio
2.5928 of 5 stars
$4.45
-3.5%
$17.33
+289.5%
-6.8%$193.99MN/A0.003High Trading Volume
SCLX
Scilex
2.8666 of 5 stars
$0.99
+1.1%
$11.33
+1,041.4%
-46.3%$190.43M$46.74M-0.6980Gap Up
ATAI
Atai Life Sciences
2.0102 of 5 stars
$1.13
-7.4%
$10.50
+829.2%
-9.2%$189.17M$378,000.00-2.8283Positive News
DMAC
DiaMedica Therapeutics
1.6105 of 5 stars
$4.32
+0.5%
$7.00
+62.0%
+86.4%$184.67MN/A-8.1520Positive News
ATOS
Atossa Therapeutics
1.1609 of 5 stars
$1.43
-1.4%
$6.25
+337.1%
+110.3%$179.83MN/A-6.818Analyst Forecast
News Coverage

Related Companies and Tools


This page (NASDAQ:AFMD) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners